Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis,
19 mins; November 13, 2025
Unique Challenges Characterize Treatment Outcomes for Women With Bladder Cancer: With Martha K. Terris, MD, FACS
4 mins; November 11, 2025
Urothelial ESMO 2025 Updates
13 mins; November 10, 2025
Research Innovations Spark Promise for Broadening the HR+ Breast Cancer Armamentarium Post-CDK4/6 Inhibition: With Kevin Kalinsky, MD, MS, FASCO
9 mins; November 07, 2025
ARROS-1 Data Show Zidesamtinib's Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD
11 mins; November 06, 2025
Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC
4 mins; November 06, 2025
Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO
19 mins; November 05, 2025
Bladder Cancer Symptom Awareness and Testing Are Crucial for Early Detection in Women: With Martha K. Terris, MD, FACS
5 mins; November 04, 2025
Oncology Experts Dive Into Top Data From ESMO 2025
17 mins; November 03, 2025
Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS
12 mins; October 31, 2025
Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD
29 mins; October 30, 2025
Evolving Research Paradigms, Real-World Data, and Multidisciplinary Collaboration Enhance Bladder Cancer Management: With Amit Mehta, MD
26 mins; October 29, 2025
FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD
15 mins; October 27, 2025
FDA Approval Insights: Adjuvant Cemiplimab for High-Risk CSCC: With Vishal A. Patel, MD, FAAD, FACMS
12 mins; October 23, 2025
Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
32 mins; October 23, 2025
Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD
13 mins; October 22, 2025
Metastatic Breast Cancer 2025 UPDATE
11 mins; October 20, 2025
FDA Approval Insights: Subcutaneous Pembrolizumab for Solid Tumors: With J. Thaddeus Beck, MD, FACP
4 mins; October 16, 2025
Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD
38 mins; October 15, 2025
Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress
13 mins; October 13, 2025
FDA Approval Insights: Gemcitabine Intravesical System for NMIBC: With Joseph Jacob, MD, MCR
11 mins; October 09, 2025
FDA Approval Insights: Sunvozertinib in EGFR-Mutated Metastatic NSCLC: With Lyudmila Bazhenova, MD
5 mins; October 08, 2025
Sequencing, Efficacy, and Safety Data May Further Evolve the Role of Fruquintinib in CRC: With Kanwal P. S. Raghav, MBBS, MD
9 mins; October 06, 2025
FDA Approval Insights: Maintenance Lurbinectedin Plus Atezolizumab for ES-SCLC: With Anne Chiang, MD, PhD; and Stephen Liu, MD
12 mins; October 02, 2025
Early Biomarker Testing Optimizes Tepotinib Use in NSCLC With MET Exon 14 Skipping Mutations: With Stephen Liu, MD
9 mins; October 01, 2025
Expanding JAK Inhibitor Use Offers Increased Treatment Options for Cytopenic Myelofibrosis: With Andrew Kuykendall, MD
11 mins; September 29, 2025
Early CAR T-Cell Therapy Data Highlight Therapeutic Potential and Emerging Challenges in GI Cancers: With Kohei Shitara, MD
8 mins; September 25, 2025
The Evolving Role of Noncovalent BTK Inhibition Informs CLL Treatment Selection: With Asad Dean, MD
16 mins; September 24, 2025
Zidesamtinib Is Associated With CNS Activity and Low Rates of Neurologic AEs in Pretreated ROS1+ NSCLC: With Alexander Drilon, MD
8 mins; September 18, 2025
Patient Characteristics and Disease Factors Guide the Use of Dostarlimab in Recurrent Endometrial Cancer: With Dana M. Chase, MD
16 mins; September 17, 2025
Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC
18 mins; September 16, 2025
Establishing the Rationale for ADC and ICI Combinations in TNBC
18 mins; September 16, 2025
Cohort Analysis Shows Importance of Early-Onset CRC Awareness and Investigation: With Evelyn Y. Wong, MD
7 mins; September 15, 2025
Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC
18 mins; September 15, 2025
Dissecting Clinical Trial and Real-World Data for ADCs in TNBC
20 mins; September 15, 2025
Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC
17 mins; September 12, 2025
Breaking Down the Rationale for Targeting TROP2 in TNBC
14 mins; September 12, 2025
Patient Characteristics and Care Team Collaboration Influence Treatment Decision-Making in CLL: With John N. Allan, MD; and Melissa Rubianes
15 mins; September 11, 2025
Tepotinib Efficacy and Safety Profiles Underscore the Importance of Biomarker-Directed Decision-Making in NSCLC: With Balazs Halmos, MD, MS
13 mins; September 09, 2025
Recent FDA Approvals and Ongoing Research Expand Treatment Options for Soft Tissue Sarcoma: With Samantha A. Armstrong, MD; and Karine Tawagi, MD
21 mins; September 08, 2025
Clinical Trial and Real-World Data With NALIRIFOX Shape the Future of Pancreatic Cancer Care: With Tara E. Seery, MD; Paul E. Oberstein, MD; and Priyadarshini Pathak, MBBS
15 mins; September 04, 2025
Advances in ctDNA Testing Guide Clinical Decision-Making in GI Cancer Management: With Scott Kopetz, MD, PhD, FACP
21 mins; September 03, 2025
Safety and Quality-of-Life Considerations Shape ADT Use in Prostate Cancer: With Tanya B. Dorff, MD
15 mins; September 02, 2025
FDA Approval Insights: Dordaviprone in H3K27M-Mutated Diffuse Midline Glioma: With Patrick Y. Wen, MD
10 mins; September 01, 2025
FDA Approval Insights: Taletrectinib in ROS1+ Advanced/Metastatic NSCLC: With Joel Neal, MD, PhD; and Christian Rolfo, MD, PhD
14 mins; August 28, 2025
FDA Approval Insights: Zongertinib in HER2-Mutated NSCLC: With Ticiana Leal, MD, and Misako Nagasaka, MD, PhD
15 mins; August 27, 2025
Obe-Cel Data Are Poised to Refine and Expand the ALL Treatment Paradigm: With Aaron Logan, MD, PhD; and Bijal Shah, MD, MS
39 mins; August 26, 2025
SUPRAME Trial Propels the Development of TCR-Based Therapy in Cutaneous Melanoma: With Jason Luke, MD
7 mins; August 25, 2025
Distinguishing Pathway to Precision for c-Met and MET Alterations in NSCLC
24 mins; August 22, 2025
Refining First-Line Immunotherapy Strategies in Hepatocellular Carcinoma: With Masatoshi Kudo, MD, PhD
7 mins; August 21, 2025
Multidisciplinary Collaboration Gives Forward Momentum to HER2 IHC Testing in NSCLC: With Ronan J. Kelly, MD, MBA, FASCO; and Michelle Shiller, DO, AP/CP, MGP
21 mins; August 19, 2025
FDA Approval Insights: Linvoseltamab in Relapsed/Refractory Multiple Myeloma: With Nisha Joseph, MD; and Hans Lee, MD
12 mins; August 18, 2025
Exploring NCCN Guideline Updates and Advancing Immunotherapy Strategies in Nasopharyngeal Carcinoma: With Neal S. Akhave, MD
10 mins; August 14, 2025
Frank’s Path to Advancing Hematology Through Innovation and Discovery: With Girindra Raval, MD; and David A. Frank, MD, PhD, FACP
40 mins; August 13, 2025
Real-World Perspectives on mCRC and GI Neuroendocrine Neoplasms; With RocĂo GarcĂa-Carbonero, MD, PhD
11 mins; August 12, 2025
Endometrial (Uterine) Cancer 2025 UPDATE
12 mins; August 11, 2025
The European Approval of Mirdametinib Expands the Treatment Paradigm for NF1-Associated Plexiform Neurofibromas: With Ignacio Blanco, MD, PhD
6 mins; August 07, 2025
The Role of Combination Checkpoint Blockade Is Evolving in MSI-H mCRC: With Elena Élez, MD, PhD
10 mins; August 06, 2025
Efficacy of Immune Checkpoint Inhibition in Oncology May Translate to Neurologic Disorders: With Shailee S. Shah, MD
17 mins; August 05, 2025
Guideline Updates and Trial Data Solidify the Role of HER2/MET IHC Testing in NSCLC: With Martin F. Dietrich, MD, PhD
26 mins; August 04, 2025
Retrospective Data Highlight Improved Efficacy With Maintenance Therapy vs Treatment Breaks in mCRC: With Connie Lai, MD
5 mins; July 31, 2025
CRISPR-Edited CISH Knockout TIL Therapy Paves Novel Treatment Paths in CRC: With Branden Moriarity, PhD; and Beau Webber, PhD
15 mins; July 28, 2025
Telisotuzumab Vedotin Represents a New Treatment Development for c-Met–Overexpressing NSCLC: With Joshua K. Sabari, MD
9 mins; July 24, 2025
Cortes’ Journey Helps Reshape Hematologic Cancer Care: With Girindra Raval, MD; and Jorge Cortes, MD
45 mins; July 23, 2025
Isatuximab-Based Triplet Delivered via On-Body System Shows Promise in RRMM: With Xavier Leleu, MD, PhD; and Beth Faiman, PhD, MSN, APN-BC
21 mins; July 21, 2025
European Approval of Zanidatamab Expands Treatment Options for HER2+ Biliary Tract Cancer: With Arndt Vogel, MD
11 mins; July 17, 2025
IHC Testing Leads to Early Detection of TP53-Mutant AML and MDS: With Jonathan M. Gerber, MD; and Shyam A. Patel, MD, PhD
28 mins; July 16, 2025
Biopsy-Guided Approach Enables Surgery Omission After pCR in HER2+ and Triple-Negative Breast Cancer: With Henry M. Kuerer, MD, PhD, FACS, CMQ
18 mins; July 15, 2025
FDA Approval Insights: Oncomine DX Express Test Companion Diagnostic for Sunvozertinib in Non–Small Cell Lung Cancer: With Apar Kishor Ganti, MD; and Allison Cushman-Vokoun, MD, PhD, FCAP
11 mins; July 14, 2025
Toripalimab Plus De-Intensified Chemo Represents the Potential Future of Nasopharyngeal Cancer Management: With Justine Bruce, MD
11 mins; July 10, 2025
How Enthusiasm for Science and Global Change Culminates in Wide-Reaching Opportunities to Improve Cancer Care: D. Ross Camidge, MD, PhD; and Catharine Young, PhD
69 hours 16 mins; July 09, 2025
ASCO 2025 Plenary — MATTERHORN
12 mins; July 07, 2025
FDA Approval Insights: Darolutamide for Metastatic Castration-Sensitive Prostate Cancer: With Alicia Morgans, MD, MPH; and Neal Shore, MD, FACS
16 mins; July 03, 2025
Biomarker-Directed Therapies Improve Outlooks for the mCRC Treatment Arsenal: With Chandler Park, MD; and Midhun Malla, MD
6 mins; July 02, 2025
IMA203 emerges as a Novel Investigational Agent in Cutaneous Melanoma: With Justin Moser, MD
7 mins; June 30, 2025
BRAF-Mutant and HER2+ mCRC Management Strategies Are Becoming Increasingly Tailored: With Chandler Park, MD, and Midhun Malla, MD
9 mins; June 26, 2025
T-DXd's Efficacy Stands Strong and Supports IHC Testing in HER2-Mutated NSCLC: With Misako Nagasaka, MD, PhD
6 mins; June 25, 2025
ASCO 2025 Plenary: SERENA-6
12 mins; June 24, 2025
Long-Term Data Underscore the Enduring Efficacy of PD-1 Inhibition in Nasopharyngeal Carcinoma: With Michael Dennis, MD
15 mins; June 23, 2025
Conversations About BTK Inhibitors and CAR T-Cell Therapies Bridge Gaps in Leukemia and Lymphoma: With Alexey Danilov, MD, PhD
19 mins; June 19, 2025
42nd Annual Miami Breast Cancer Conference® Podcast: OncLive On Air CE, Powered by PER
26 mins; June 18, 2025
Liquid Imatinib Formulation Expands Leukemia Treatment Options and Improves Treatment Adherence: With Kate Gasparini, PharmD, BCOP, BCPPS
11 mins; June 17, 2025
The Expanding Role of AR Inhibition in mHSPC Management: With Alicia Morgans, MD, MPH
11 mins; June 16, 2025
Revumenib Shows Promise Across Menin-Sensitive AML Subtypes and Could Shift Treatment Paradigms: With Naval Daver, MD
11 mins; June 12, 2025
T-DXd Plus Pertuzumab Could Redefine First-Line HER2+ Breast Cancer Management: With Paolo Tarantino, MD
14 mins; June 11, 2025
Telisotuzumab Vedotin Shakes Up Management of Pretreated, c-MET–Overexpressing NSCLC: With Jonathan W. Goldman, MD
9 mins; June 10, 2025
Collaborative Structural Reforms Represent a Way Forward for Oncology Innovations: With Elizabeth Mittendorf, MD, PhD, MHCM
9 mins; June 09, 2025
Updates and Innovations in Non-Opioid Pain Management Strategies for Breast Cancer Patients Post-Surgical Intervention
92 hours 30 mins; June 04, 2025
Multidisciplinary Collaboration and Mentorship Lay the Foundation for a New Chapter of ASCO Leadership: With Elizabeth Mittendorf, MD, PhD, MHCM
12 mins; June 02, 2025
Oncology PER® Spectives: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma
54 mins; June 02, 2025
Evolving Molecular Profiling and Liquid Biopsy Practices Guide First-Line CRC Therapy Decisions: With Chandler Park, MD; and Midhun Malla, MD
9 mins; May 29, 2025
FDA Approval Insights: Perioperative Durvalumab Plus Chemo in MIBC: With Matthew Galsky, MD
7 mins; May 28, 2025
Social Media Expands Access to Practical Public Health Education: With Chandler Park, MD; and Paul Hanona, MD
8 mins; May 26, 2025
Eltrombopag Biosimilar Improves Accessibility for Immune Thrombocytopenia & Aplastic Anemia: With Kanwarpal S. Kahlon, MD
8 mins; May 22, 2025
Updated Nilotinib Formulation Improves Treatment Adherence in Ph+ CML: With Michael J. Mauro, MD
12 mins; May 19, 2025
Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer
49 mins; May 19, 2025
Cancer Vaccines Shake Up Disease Management and Prevention Strategies: With Shubham Pant, MD, MBBS; and Professor Timothy Elliott
24 mins; May 15, 2025
Optimizing Today and Looking to Tomorrow in Metastatic CRPC - Homing in on EZH2
43 mins; May 14, 2025
MEK Inhibitors Expand the NF1-Associated PN Treatment Paradigm: With Christopher L. Moertel, MD
12 mins; May 12, 2025
Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation
